From Ultra-Processed Food to GLP-1 Prescriptions Part 1

A systems problem disguised as a medical solution

Over the past decade, a quiet shift has taken place in Western health systems.

Instead of addressing the upstream causes of metabolic dysfunction, we have increasingly turned to downstream pharmaceutical interventions. GLP-1 medications and peptide therapies are now being prescribed at scale to manage obesity, insulin resistance, and visceral fat accumulation.

On the surface, this looks like progress. In reality, it raises a more uncomfortable question.

Are we treating a biological problem, or compensating for a food system failure?

As Craig Astill has often argued, when medicine expands rapidly to manage conditions that were rare a generation ago, it is rarely because biology has changed. It is because systems have. Here what you need to know. From Ultra-Processed Food to GLP-1 Prescriptions

The rise of ultra-processed food as a metabolic stressor

Modern diets in developed nations are now dominated by ultra-processed and ultra-synthesised food-like products. These are not simply “convenient foods.” They are engineered inputs designed for shelf life, palatability, and profit optimisation rather than metabolic compatibility.

These products are typically characterised by:

High glycaemic load
Low fibre and micronutrient density
Artificial flavouring and texture agents
Industrial seed oils and refined carbohydrates
Additives that disrupt satiety signalling

Over decades, consistent exposure to these inputs has altered how the body regulates hunger, insulin, and fat storage. Visceral fat accumulation, insulin resistance, and metabolic inflammation are not anomalies in this context. They are predictable outcomes.

From a systems perspective, this is not a failure of individual discipline. It is the result of long-term exposure to inputs the human body was never designed to process at scale.

GLP-1s and peptides as a form of metabolic shock

GLP-1 medications work by manipulating appetite, satiety, and glucose regulation. They slow gastric emptying, suppress hunger signals, and alter how the brain interprets energy intake.

They are effective. That is not in dispute.

But they operate as biological overrides, not corrections. They force the system into a new state without changing the inputs that caused the dysfunction in the first place.

In many cases, these medications are prescribed precisely because lifestyle and dietary interventions have failed. But that framing misses the deeper issue. Those interventions failed within an environment saturated with ultra-processed food, time pressure, and economic incentives that favour poor nutrition.

The body is being shocked into compliance because the system it operates within has not been redesigned.

The $400 question

GLP-1 therapies now commonly cost around $400 per month, often indefinitely.

This raises a question that is rarely asked directly.

Is $400 per month better spent on drugs designed to trick appetite and metabolism, or on consistently high-quality food that aligns with human biology?

This is not a moral argument. It is a systems one.

High-quality whole foods reduce metabolic stress. They improve insulin sensitivity, satiety signalling, and inflammatory load. They address cause rather than consequence. But they require structural support: access, time, education, and cultural reinforcement.

Pharmaceuticals are easier to deploy because they fit within existing systems. They scale. They monetise well. They require no redesign of food production, marketing, or supply chains.

From a capital and infrastructure perspective, the answer is obvious. From a health perspective, the trade-off is less comfortable.

When medicine becomes a substitute for prevention

Western medicine excels at intervention. It is far less effective at prevention when prevention requires system redesign.

GLP-1 prescribing at scale reflects a broader pattern. Instead of questioning why metabolic disease has become normalised, we normalise lifelong medication to manage it.

As Craig Astill has highlighted in broader health and systems analysis, when downstream systems are asked to compensate for upstream failures, costs do not disappear. They accumulate. Financially, biologically, and socially.

Medicine can suppress symptoms. It cannot erase decades of dietary and metabolic conditioning.

This is not an argument against medicine

GLP-1s and peptide therapies have legitimate clinical use. For some individuals, they provide critical support. This is not a rejection of medical science.

It is a call to stop pretending that pharmaceutical intervention is a substitute for fixing the system that made such intervention necessary.

If ultra-processed food remains the default input, medical overrides will remain the default response.

Setting up the series

This article is the first in a series examining how modern health outcomes are shaped less by individual choice and more by system design.

Future pieces will explore:

How food manufacturing incentives drive metabolic disease
Why prevention struggles to compete with treatment in capital systems
The long-term implications of normalising pharmaceutical appetite control
What a biologically aligned food system would actually require

The question is not whether GLP-1s work.

The question is whether we are willing to invest in fixing the system that made them necessary in the first place.

Because if we are not, we should at least be honest about what we are paying for.